Shilpa Lingaiah, Laure Morin-Papunen, Juha Risteli, Juha S. Tapanainen, Metformin decreases bone turnover markers in polycystic ovary syndrome: a post hoc study, Fertility and Sterility, Volume 112, Issue 2, 2019, Pages 362-370, ISSN 0015-0282, https://doi.org/10.1016/j.fertnstert.2019.04.013
Metformin decreases bone turnover markers in polycystic ovary syndrome : a post hoc study
|Author:||Lingaiah, Shilpa1; Morin-Papunen, Laure1; Risteli, Juha2;|
1Department of Obstetrics and Gynecology, PEDEGO Research Unit, Medical Research Centre, Oulu University Hospital and University of Oulu, Oulu, Finland
2Department of Clinical Chemistry, Oulu University Hospital, Oulu, Finland
3Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
|Online Access:||PDF Full Text (PDF, 0.6 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2019082725784
|Publish Date:|| 2020-06-18
Objective: To study the effects of metformin treatment on bone turnover in women with polycystic ovary syndrome (PCOS), as measured by serum concentrations of bone turnover markers.
Design: Post hoc study of a previously conducted prospective multicenter, placebo-controlled, randomized study.
Setting: University clinic.
Patient(s): The study cohort consisted of 74 non-obese women (body mass index < 27 kg/m²) and 44 obese women (body mass index ≥ 27 kg/m²) diagnosed with PCOS, with a mean age of 27.6 ± 4.0 (SD) years.
Intervention(s): Randomization to receive metformin or placebo for 3 months.
Main Outcome Measure(s): Serum levels of bone formation marker procollagen type I amino-terminal propeptide (PINP) and bone resorption marker carboxy-terminal cross-linking telopeptide of type I collagen (CTX) at baseline and after metformin/placebo treatment.
Result(s): Serum levels of PINP and CTX were similar between the metformin and placebo groups at baseline in the whole study population. Obese women, when compared with non-obese, had lower baseline levels of PINP and CTX. Levels of PINP and CTX were significantly reduced in the whole study population, as well as in both non-obese and obese women after 3 months of metformin treatment, whereas no significant changes were observed in the placebo group.
Conclusion(s): Metformin treatment, when compared with placebo, was associated with reduced bone turnover, as suggested by reductions in markers of bone formation and resorption, leading to slower bone remodeling in premenopausal women with PCOS.
Fertility and sterility
|Pages:||362 - 370|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3123 Gynaecology and paediatrics
© 2019 Published by Elsevier Inc. on behalf of the American Society for Reproductive
Medicine. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/.